Cargando…
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
OBJECTIVE: To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer. METHODS: This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive relapsed, high-grade serous ovarian, fallopian tube, or p...
Autores principales: | Okamoto, Aikou, Kondo, Eiji, Nakamura, Toshiaki, Yanagida, Satoshi, Hamanishi, Junzo, Harano, Kenichi, Hasegawa, Kosei, Hirasawa, Takeshi, Hori, Kensuke, Komiyama, Shinichi, Matsuura, Motoki, Nakai, Hidekatsu, Nakamura, Hiroko, Sakata, Jun, Tabata, Tsutomu, Takehara, Kazuhiro, Takekuma, Munetaka, Yokoyama, Yoshihito, Kase, Yoichi, Sumino, Shuuji, Soeda, Junpei, Suri, Ajit, Aoki, Daisuke, Sugiyama, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930437/ https://www.ncbi.nlm.nih.gov/pubmed/33327047 http://dx.doi.org/10.3802/jgo.2021.32.e16 |
Ejemplares similares
-
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer
por: Takehara, Kazuhiro, et al.
Publicado: (2021) -
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021) -
Niraparib for ovarian cancer
Publicado: (2021) -
Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer
por: Takamatsu, Shiro, et al.
Publicado: (2023) -
Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)